Medication Abortion

Answers for health care providers about birth control options after abortion

Young people’s concerns about birth control and fertility, expanding EPT and PrEP in the ED, spike in EC demand around the New Year, and abortion decision making.

Highlighting one notable research article from each Research Roundup in 2023.

Pain management during procedural abortion, serum etonogestrel levels not associated with mood changes during implant use, and clinical considerations when patients are traveling for abortion care.

Pain management in abortion care, risk of Rh sensitization with abortion before 12 weeks’ gestation, and contraception information on TikTok.

Answers for pharmacists (and other providers) about the current status of mifepristone.

COX-2 inhibitor demonstrates potential in increasing efficacy of OTC LNG-EC pills; updated systematic review and meta-analysis supporting the effectiveness and safety of misoprostol-alone for medication abortion; support needs of adolescents and young adult abortion seekers; and more!

Continued support for misoprostol-only regimens for medication abortion and self-managed abortion between nine and 16 weeks gestation, the use of home pregnancy tests for follow-up care after a telehealth medication abortion, where adolescents and young adults go online to get abortion information, and disparities in recommended retesting for women with trichomonas vaginalis infections.